Parkinsonismo
Keywords:
Parkinson’s disease, juvenile Parkinson’s, parkinsonism.Abstract
Parkinson’s disease (PD) is the most frequent movement disorder among Parkinsonian
syndromes, however during the more than 200 years of its discovery by James Parkinson
in 1817, a wide variety of associated disorders have been described that vary according
to the age of presentation, clinical manifestations, and etiology, one of them is juvenile
parkinsonism (JP). JP is characterized by classic symptoms of parkinsonism such as
bradykinesia (the main one), associated with resting tremor or stiffness, which begin in
patients under 21 years of age.
It is currently considered a rare entity with an incidence in the United States of 0.8 per
100,000 people/year between the ages of 0 and 29. Its etiology varies, the most frequent
cause being the mutation of certain genes such as PARK2 (the most frequent), PINK1
and PARK7, among others. The treatment scheme of JP is currently based on dopamine
agonists and levodopa, similar to those used in later presentations, however due to the
little information available about JP, it has become a challenge for the neurologist asking
for its management, it is for this reason that we carried out a systematic review of the
literature of the most updated treatment schemes in order to expand the knowledge to
improve the quality of life of this population group.
References
Leuzzi V, Nardecchia F, Pons R, Galosi S. Parkinsonism in children: Clinical classification and etiological spectrum. Parkinsonism Relat Disord [Internet]. 2021; 82:150–7.
Vallejo Zambrano CR, Jiménez Jiménez RA, Morán Rodríguez VE, Gómez Chumo ME, Del Valle Pilay MB, Palma Moreno NJ. Síndrome de Parkinson: Revisión bibliográfica y actualización. Anál comport las líneas crédito través corp financ nac su aporte al desarro las PYMES Guayaquil 2011-2015 [Internet]. 2020;4(4):270–81.
Del Rey NL-G, Quiroga-Varela A, Garbayo E, Carballo-Carbajal I, Fernández-Santiago R, Monje MHG, et al. Advances in Parkinson’s disease: 200 years later. Front Neuroanat [Internet]. 2018; 12:113.
Niemann N, Jankovic J. Juvenile parkinsonism: Differential diagnosis, genetics, and treatment. Parkinsonism Relat Disord [Internet]. 2019; 67:74–89.
Anwar A, Saleem S, Akhtar A, Ashraf S, Ahmed MF. Juvenile Parkinson disease. Cureus [Internet]. 2019;11(8):e5409.
Simon DK, Tanner CM, Brundin P. Parkinson disease epidemiology, pathology, genetics, and pathophysiology. Clin Geriatr Med [Internet]. 2020;36(1):1–12.
Jankovic J, Tan EK. Parkinson’s disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry [Internet]. 2020;91(8):795–808.
Hong S, Lee S, Cho S-R. Juvenile parkinsonism with PARK2 gene mutation misdiagnosed as dopa-responsive dystonia: A case report. Brain neurorehabilit [Internet]. 2020;13(2).
Zhang P-L, Chen Y, Zhang C-H, Wang Y-X, Fernandez-Funez P. Genetics of Parkinson’s disease and related disorders. J Med Genet [Internet]. 2018;55(2):73–80.
Li J-Y, Li N-N, Wang L, Peng J-X, Duan L-R, Chen C-L, et al. A compound heterozygous PINK1-associated juvenile Parkinson’s disease with pregnancy in Chinese. J Neurol [Internet]. 2021;268(6):2223–7.
Riboldi GM, Frattini E, Monfrini E, Frucht SJ, Di Fonzo A. A practical approach to early-onset parkinsonism. J Parkinsons Dis [Internet]. 2022;12(1):1–26.
Fernández-Espejo E.Microorganisms that are related with increased risk for Parkinson’s disease. Neurol (Engl Ed) [Internet].2020.
Radhakrishnan DM, Goyal V. Parkinson’s disease: A review. Neurol India[Internet].2018[cited 2022 Mar 10];66(Supplement):S26–35.
Anali C-A, Ángel A-H. Prevalencia de síntomas no motores en pacientes con enfermedad de parkinson: una revision. Revista Médica Panacea [Internet]. 2019;7(3).
Carrillo García F. Enfermedad de Parkinson y parkinsonismos.Medicine [Internet]. 2019;12(73):4273–84.
Saavedra Moreno JS, Millán PA, Buriticá Henao OF. Introducción, epidemiología y diagnóstico de la enfermedad de Parkinson. Acta neurol colomb [Internet]. 2019;35(3 supl. 1):2–10.
Ospina-García N, et al. Etiología, fenomenología, clasificación y tratamiento de la distonía. Rev Mex Neurocienc [Internet]. 2018;19(4):94–107.
Urquizo Rodríguez EI, Molina Campoverde S del C, Aguirre Molina MJ, Triviño Sánchez JS. Enfermedad de Parkinson, su asociación con los síntomas no motores. RECIAMUC [Internet]. 2020;4(1):15–28.
Marín DS, Carmona H, Ibarra M, Gámez M, et al. Enfermedad de Parkinson: fisiopatología, diagnóstico y tratamiento. Rev Univ Ind Santander Salud [Internet]. 2018;50(1):79–92.
Henao Piedrahita N, Pérez Correa S, Vásquez Builes S, Díaz Silva GA. Manifestaciones cardiovasculares de la enfermedad de Parkinson: revisión de la literatura. Acta neurol colomb [Internet]. 2021;37(2):91–7.
Morales-Briceño H, Mohammad SS, Post B, Fois AF, Dale RC, Tchan M, et al. Clinical and neuroimaging phenotypes of genetic parkinsonism from infancy to adolescence. Brain [Internet]. 2020;143(3):751–70.
Chaves Morales KP, Padilla Elizondo DS, Vargas Fernández R. Enfermedad de Parkinson. Rev Medica Sinerg [Internet]. 2022;7(2):e758.
Costa MFBNA da, Reisdorfer E, Kempfer SS, Fernandes GCM, Porporatti AL, Canto GDL. Diagnostic validity of biomarkers in Parkinson’s Disease: systematic review and meta-analysis. Rev Bras Enferm [Internet]. 2018;71(6):3074–83.
Li T, Le W. Biomarkers for Parkinson’s disease: How good are they? Neurosci Bull [Internet]. 2020;36(2):183–94.
Upadhya R, Shetty AK. Extracellular vesicles for the diagnosis and treatment of Parkinson’s disease. Aging Dis [Internet]. 2021;12(6):1438–50.
Rojas Castillo JC, Ruiz AM, Moreno López CL, Silva Soler MA, Páez Gutiérrez CC. Parkinson genético: Reporte de un caso clínico y revisión de la literatura. Acta neurol colomb [Internet]. 2021;37(3):133–8.
Rubio S, Pacheco-Orozco RA, Gómez AM, Perdomo S, García-Robles R. Secuenciación de nueva generación (NGS) de ADN: presente y futuro en la práctica clínica. Univ Médica [Internet]. 2020;61(2).
Carrillo García F. Protocolo diagnóstico de la enfermedad de Parkinson y otros parkinsonismos. Medicine [Internet]. 2019;12(73):4313–5.
Kerstens VS, Varrone A. Dopamine transporter imaging in neurodegenerative movement disorders: PET vs. SPECT. Clin Transl Imaging [Internet]. 2020;8(5):349–56.
Yao N-T, Zheng Q, Xu Z-Q, Yin J-H, Lu L-G, Zuo Q, et al. Positron emission computed tomography/single photon emission computed tomography in Parkinson disease. Chin Med J (Engl) [Internet]. 2020;133(12):1448–55.
Jiang L, Wang X, Li P, Feng Z, Shi X, Shao H. Efficacy of 11C-2β-carbomethoxy-3β-(4-fluorophenyl) tropane positron emission tomography combined with 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of early Parkinson disease: A protocol for systematic review and meta analysis. Medicine (Baltimore) [Internet]. 2020;99(51):e23395.
Rozo-Moreno, M. K., Celis-Torres, Y. L., & Becerra-Hernández, L. (2021). Alternativas terapéuticas para la enfermedad del Parkinson. Salutem Scientia Spiritus, 7.
Zesiewicz TA. Parkinson disease. Continuum (Minneap Minn) [Internet]. 2019;25(4):896–918.
Movimientos Anormales C. Medicamentos utilizados en la enfermedad de Parkinson: guía práctica. Acta neurol colomb [Internet]. 2019;35(3 supl. 1):75–9.
Mao Q, Qin W-Z, Zhang A, Ye N.Recent advances in dopaminergic strategies for the treatment of Parkinson’s disease. Acta Pharmacol Sin [Internet]. 2020;41(4):471.
Sharma VD, Patel M, Miocinovic S. Surgical treatment of Parkinson’s disease: Devices and lesion approaches. Neurotherapeutics [Internet]. 2020;17(4):1525–38.
Mitchell KT, Ostrem JL. Surgical treatment of Parkinson disease. Neurol Clin [Internet]. 2020;38(2):293–307.
Axelsen TM, Woldbye DPD. Gene therapy for Parkinson’s disease, an update. J Parkinsons Dis[Internet].2018;8(2):195–215.
Vargas Jaramillo JD, Barrios Vincos G. Tratamiento de la enfermedad de Parkinson temprana. Acta neurol colomb [Internet]. 2019;35(3 supl. 1):11–8.
Ellis T, Rochester L. Mobilizing Parkinson’s disease: The future of exercise. J Parkinsons Dis [Internet]. 2018;8(s1):S95–100.
Fearon C, Fasano A. Parkinson’s disease and the COVID-19 pandemic. J Parkinsons Dis [Internet]. 2021;11(2):431–44.
Kouli A, et al. Parkinson’s Disease: Etiology, Neuropathology, and Pathogenesis. En: Parkinson’s Disease: Pathogenesis and Clinical Aspects. Codon Publications; 2018.
Picca A, Guerra F, Calvani R, Romano R, Coelho-Júnior HJ, Bucci C, et al. Mitochondrial dysfunction, protein misfolding and neuroinflammation in Parkinson’s disease:Roads to biomarker discovery. Biomolecules [Internet]. 2021;11(10):1508.
de Bie RMA, Clarke CE, Espay AJ, Fox SH, Lang AE. Initiation of pharmacological therapy in Parkinson’s disease: when, why, and how. Lancet Neurol [Internet]. 2020;19(5):452–61.
Ellis T, Rochester L. Mobilizing Parkinson’s disease: The future of exercise. J Parkinsons Dis [Internet]. 2018;8(s1):S95–100.
Cilia R, Bonvegna S, Straccia G, Andreasi NG, Elia AE, Romito LM, et al. Effects of COVID-19 on Parkinson’s disease clinical features: A community-based case-control study. Mov Disord [Internet]. 2020;35(8):1287–92.
Helmich RC, Bloem BR. The impact of the COVID-19 pandemic on Parkinson’s disease: Hidden sorrows and emerging opportunities. J Parkinsons Dis [Internet]. 2020;10(2):351–4.
Dorsey ER, Sherer T, Okun MS, Bloem BR. The emerging evidence of the Parkinson pandemic. J Parkinsons Dis [Internet]. 2018;8(s1):S3–8.
Antonini A, Moro E, Godeiro C, Reichmann H. Medical and surgical management of advanced Parkinson’s disease. Mov Disord [Internet]. 2018;33(6):900–8.
Franco G, Lazzeri G, Di Fonzo A. Parkinsonism and ataxia. J Neurol Sci [Internet]. 2022;433(120020):120020.
Downloads
Published
Versions
- 2025-11-14 (4)
- 2025-11-14 (3)
- 2025-11-14 (2)
- 2022-05-05 (1)
How to Cite
Issue
Section
License
Copyright (c) 2022 Scientific and Eduaction Medical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Atribución – No comercial – Compartir igual: Esta licencia permite a otros distribuir, remezclar, retocar, y crear a partir de tu obra de modo no comercial, siempre y cuando te den crédito y licencien sus nuevas creaciones bajo las mismas condiciones.
Attribution-NonCommercial-ShareAlike 4.0 International
